Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DIMERIX LIMITED Director's Dealing 2014

Dec 23, 2014

64804_rns_2014-12-23_082e03b3-21e1-43e9-8235-91fff3511fcb.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Sun Biomedical Limited
ABN 18 001 285 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

director for the purposes of section 205G of t director for the purposes of section 205G of t director for the purposes of section 205G of t he Corporations Act.
Name of Director D r Anton Uvarov
Date of last notice 5 December 2014

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

oe: n e case o a company, neress wc come wn paragradisclosed in this part. oe: n e case o a company, neress wc come wn paragradisclosed in this part. oe: n e case o a company, neress wc come wn paragradisclosed in this part. () o e enon o noae eres o a recor sou e eres o a recor sou e
Direct or indirect interestDirect
Direct or indirect interest Direct
Nature of indirect interest N/A
(including registered holder)Note: Provide details of the circumstances
giving rise to the relevant interest.
Date of change 22 Decembe r 2014
No of securities held rior to 1000000
. pchange ,,
Class Fully paid o rdinary shares
Number acquired 402,019
Number disosed
p -
Value/Considerationincludes brokerage/gst $2,834.08
Note: If consideration is non-cash, providedetails and estimated valuation
  • See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after 1,402,019 fully paid ordinary shares change

Nature of change Purchase of shares on-market Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest N/A
Name of registered holder(if issued securities) N/A
Date of change N/A
No. and class of securities towhich interest related prior tochangeNote: Details are only required for a contract in relationto which the interest has changed N/A
Interest acquired N/A
Interest disposed N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and anestimated valuation N/A
Interest after change N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed N/A above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was N/A this provided?

  • See chapter 19 for defined terms.

Appendix 3Y Page 2